Journal articles: 'Lympohma'

1

Sakorafas, George H., Panayiottis Kokkoris, and David R. Farley. "Primary thyroid lympoma." Surgical Oncology 19, no. 4 (December 2010): e124-e129. http://dx.doi.org/10.1016/j.suronc.2010.06.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Villafañe, María Florencia, Norberto Trione, Marcelo Corti, Nora Mendez, Elisa Gancedo, Norberto Zamora, and Marta Levin. "Primary liver AIDS-related lympoma." Revista do Instituto de Medicina Tropical de São Paulo 48, no. 4 (August 2006): 229–31. http://dx.doi.org/10.1590/s0036-46652006000400011.

Full text

Abstract:

Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients. The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system. Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients. Ultrasonography and computed tomography scans may be helpful in the diagnosis of focal hepatic lymphoma. Image-guided fine-needle biopsy with histopathology of the liver lesions is the gold standard for the diagnosis of hepatic lymphoma. We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.

APA, Harvard, Vancouver, ISO, and other styles

3

Hussey, Daniel, and Sophie Bittinger. "Primary ovarian diffuse large B-cell lympoma." Pathology 53 (July 2021): S28. http://dx.doi.org/10.1016/j.pathol.2021.06.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

NAKAJIMA, Hiroshi, Tetsuo NAGATANI, and Naoko BABA. "Latest 10-year advance in cutis malignant lympoma." Skin Cancer 11, no. 3 (1996): 340–48. http://dx.doi.org/10.5227/skincancer.11.340.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mallaev, M. "P-077 Trigger factor in stomach MALT-lympoma." Annals of Oncology 26 (June 2015): iv21. http://dx.doi.org/10.1093/annonc/mdv233.77.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tukhvatullina, Z. "Clinical features of lympoma of the skin in Uzbekistan." Journal of the European Academy of Dermatology and Venereology 5, no. 1 (October 1995): S132. http://dx.doi.org/10.1016/0926-9959(95)96299-n.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zafar, Huma, Shazia Riaz, and Farhana Badar. "Clinical Impact of Immunophenotype-CD15/CD30 on Outcome of Hodgkin Lympoma." Blood 124, no. 21 (December 6, 2014): 2952. http://dx.doi.org/10.1182/blood.v124.21.2952.2952.

Full text

Abstract:

Abstract Introduction In classical Hodgkin Disease, Reed Sternberg cells reacts with antibodies against a granulocyte associated antigen, CD15/CD30. So expression of immunochemistries CD15 and CD 30 in patients,suspecting for HD, has quite significant diagnostic value. Aim To find out relevance of CD15/CD30 expression in relation to clinical outcome in patients of Hodgkin's disease. Methods and Material A total of 301 patients of Hodgkin' disease from stage I to stage IV treated in Shaukat Khanum hospital during last 8 years, were reviewed. Data was analyzed concerning age, gender, histopathology, staging, immunochemistry and outcome. Results: Among these 301 patients, male to female ratio was 4.3:1.The mean age was 10.01years Maximum patients presented in stage III i.e 40.2 %. Total 55 (18.2%) patients were reported positive for CD 15 and 261 (86.7 %) for CD 30. Amongst CD 15 positive patients, 1.8% received palliation, 16.3% showed Primary progressive Hodgkin's lymphoma ( PPHL ),16.3% showed relapse. Amongst CD 15 negative patients, no patients received palliation, 9.47% showed PPHL, 15.7% showed relapse. Amongst CD 30 positive patients, 0.38% pts received palliation, 7.66% showed PPHL, 12.2% showed relapse. Conclusion: There is diagnostic significance of CD15/CD 30 in Hodgkin's Disease but the prognostic significance of these immunochemistries could not be proven. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

8

Ishiji, Takaoki, Yuko Takagi, and Michihito Niimura. "Cutaneous malignant lympohomas in Tokyo: Clinical and histologic aspects." Journal of Dermatological Science 16 (March 1998): S120. http://dx.doi.org/10.1016/s0923-1811(98)83713-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Reinartz, Gabriele, Björn Kardels, Peter Koch, and Normann Willich. "Analysis of Failures after Whole Abdominal Irradiation in Gastrointestinal Lympomas." Strahlentherapie und Onkologie 175, no. 12 (December 1, 1999): 601–5. http://dx.doi.org/10.1007/s000660050047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Serke, M., A. Arias, H. Atmaca-Dirik, and M. Lehmann. "Extranodale Marginalzonen Lympome der Lunge: Beobachtungen an 9 Fällen." Pneumologie 71, S 01 (February 23, 2017): S1—S125. http://dx.doi.org/10.1055/s-0037-1598276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Derqaoui, Sabrine, Ismail Boujida, Oussama Marbouh, Lamiaa Rouas, Laila Hessissen, and Najat Lamalmi. "Non Hodgkin Lymphoma Among Children: Pathological Aspects and Diagnostic Challenges." Clinical Pathology 15 (January 2022): 2632010X2210901. http://dx.doi.org/10.1177/2632010x221090156.

Full text

Abstract:

Non-Hodgkin lymphoma (NHL) are common malignancies in children. Available data on clinico-pathological aspects of pediatric NHL in developping countries are limited and diagnostic approach appears more delicate with absence of molecular studies. The objectives of our study are: analyzing the pathological spectrum of NHL among children and highlighting challenges in the diagnosis including: limited biopsic material; unususal subtyptes, age group, or localization. We retrospectively analyzed clinico pathological characteristics of 101 NHL’s cases among children diagnosed in the Pediatric’s pathology unit over a period of 4 years There were 78 (77.2%) male and 23 (22.8%) female. The median age was 7.2 years. The most common histologic subtypes of NHL were Burkitt lymphoma in 65 patients (64.4% ); followed by lymphoblastic lymphoma in 22 patients, large B-cell lymphoma in 9 patients ( 8.9%); anaplastic T cell lymphoma in 3 patients; NOS mature T cell lymphoma and pediatric type follicular lympoma in 1 patient each. In conclusion, this study Morocco illustrates the pattern of distribution of NHL and emphasizes challenges in the diagnosis of these neoplasms.

APA, Harvard, Vancouver, ISO, and other styles

12

Riaz, Shazia, Safia Khan, and Farhana Badar. "Pediatric Hodgkin’s Lymphoma: 5-Year Experience at Single Center in Pakistan." Blood 124, no. 21 (December 6, 2014): 5455. http://dx.doi.org/10.1182/blood.v124.21.5455.5455.

Full text

Abstract:

Abstract OBJECTIVES: To review patients’ characteristics and treatment outcome pattern of pediatric hodgkinlympoma in a well funded center in developing country MATERIALS & METHOD: This was retrospective review of data of 301 pediatric hodgkin lymphoma patients up to 18 years of age treated in Shaukat Khanum Memeorial Cancer Hospital & Research Center, Lahore, Pakistan, during 2009 to 2013. RESULTS: Total No. of patients was 301, 81% were male. The median age of studied data was 9 years; ranging from 2 to 18 years. B symptoms in the form of fever, weight loss and night sweats were found in 51%, 29% and 34%, respectively. Median stage was 3 with neck bulky disease in 28% and Medistinal widening in 18% of patients. Trend of histopathology was mixed cellualrity at 56.5%. Most common treatment regime was ChlVPP/ABVD (59.5%); 30.6% of these 301 patient also got radiotherapy. At the end of treatment complete response was reported in 76.5%; 11.3% of these were relapsed afterward. CONCLUSION: Our data shows excellent outcome of pediatric hodgkin lympoma and results are comparable to that of developed countries. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

13

Guariglia, Roberto, Giuseppe Pietrantuono, Oreste Villani, Maria Carmen Martorelli, Fiorella D’Auria, Angela Zupa, Gabriella Bianchino, et al. "Combination of Rituximab, Bortezomib and Hyper-Fractionated Cyclophosphamide (RBC) in “True” Elderly Patients with Advanced Mantle Cell Lympoma." Blood 110, no. 11 (November 16, 2007): 4448. http://dx.doi.org/10.1182/blood.v110.11.4448.4448.

Full text

Abstract:

Abstract Mantle-cell lymphoma (MCL) is recognized as a distinct clinico-pathologic entity, accounting for 3–10% of all non-Hodgkin’s lymphomas, with median overall survival not exceeding 3–4 years. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The neoplastic cells are characterized as CD20+ CD5+ CD23−, with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. The current, most diffused regimens for the treatment of MCL include either R-CHOP or R-HyperCVAD, followed by autologous stem cell transplantation or observation, depending on the patient’s eligibility. However, considering that MCL is frequently diagnosed in elderly subjects with relevant co-morbidities, high dose chemotherapy or the use of drugs with potential cardiotoxicity, such as anthracyclines, may result not feasible in a significant proportion of patients. In this setting, recent data suggest that the proteasome inhibitor bortezomib is well tolerated and has significant single-agent activity in patients with MCL. Thus, we evaluated safety and efficacy of the RBC regimen, a 21-day cycle, anthracycline-free combination of rituximab (375 mg/m(2) on day 1), bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11) and hyper-fractionated cyclophosphamide (600 mg/m(2)/d given as a double, three-hour infusion on days 1–3) in “true” (≥ 75 year-old) elderly patients with advanced MCL. Diagnosis was made according to standard histological, phenotypic and molecular criteria. The results of an early analysis on feasibility in the first six patients enrolled (3 male, 3 female) are reported here. Mean age was 79.8 years (range 75–84). All patients had stage IV disease, evidencing extranodal localizations (n. 2) or marrow/leukemic involvement (n. 4). IPI score was 2 in three patients, 3 in two patients and 4 in one patient. Three patients received RBC as first line therapy, the others were treated at relapse after (R)-CHOP- like regimens. Hematological toxicities consisted in grade 1 (n. 2) and grade 2 (n. 1) thrombocytopenia, while one patient experienced grade 3 neutropenia, requiring G-CSF support. No extra-hematological toxicities higher than grade 1 were observed. Full doses of RBC were constantly administered. One patient, who presented with a WBC count > 200.000/μl, died during the first cycle due to progressive disease; another patient showed an initial response in extranodal sites and then progressed before the fourth planned cycle. The remaining four patients received six cycles: one patient achieved a partial response and three obtained a complete response, one of whom showing a molecular remission using PCR for t(11;14) bcl-1/IgH determination. All responders (66.6%) maintain their remission phase 7–10 months after the start of RBC treatment. Although very preliminary, these results indicate that RBC regimen is feasible, well tolerated and may be effective (including the possibility to obtain molecular response) in very elderly patients with advanced MCL. Larger and more mature data will be presented at the Meeting.

APA, Harvard, Vancouver, ISO, and other styles

14

Wang, Hua, Bi-bo Fu, Robert Peter Gale, and Yang Liang. "NK-/T-cell lymphomas." Leukemia 35, no. 9 (June 11, 2021): 2460–68. http://dx.doi.org/10.1038/s41375-021-01313-2.

Full text

Abstract:

AbstractNatural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein–Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- or T-cells, sometimes both. EBV-infection and subsequent genetic alterations in infected cells are central to NKTL development. Hemophagocytic syndrome is a common complication. Accurate staging is important to predict outcomes but there is controversy which system is best. More than two-thirds of NKTL lympohmas are localized at diagnosis, are frequently treated with radiation therapy only and have 5-year survival of about 70 percent. Persons with advanced NKTLs receive radiation therapy synchronously or metachronously with diverse multi-drug chemotherapy typically including l-asparginase with 5-year survival of about 40 percent. Some persons with widespread NKTL receive chemotherapy only. There are few data on safety and efficacy of high-dose therapy and a haematopoietic cell autotransplant. Immune therapies, histone deacetylase (HDAC)-inhibitors and other drugs are in early clinical trials. There are few randomized controlled clinical trials in NKTLs and no therapy strategy is clearly best; more effective therapy(ies) are needed. Some consensus recommendations are not convincingly evidence-based. Mechanisms of multi-drug resistance are considered. We discuss these issues including recent advances in our understanding of and therapy of NKTLs.

APA, Harvard, Vancouver, ISO, and other styles

15

Pagnano, KBB, J. Vassallo, I. Lorand-Metze, FF Costa, and STO Saad. "p53, Mdm, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lympomas." American Journal of Hematology 67, no. 4 (2001): 279. http://dx.doi.org/10.1002/ajh.1139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lasky, JL, NM Ponzio, and GJ Thorbecke. "Characterization and growth factor requirements of SJL lympomas. I. Development of a B cell growth factor-dependent in vitro cell line, cRCS-X." Journal of Immunology 140, no. 7 (April 1, 1988): 2478. http://dx.doi.org/10.4049/jimmunol.140.7.2478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Putri, Linda Wira, and Ardizal Rahman. "LIMFOMA MALIGNA PADA MATA YANG DIRAWAT DI RUMAH SAKIT Dr. M. DJAMIL PADANG TAHUN 2003-2010." Majalah Kedokteran Andalas 35, no. 1 (May 1, 2011): 50. http://dx.doi.org/10.22338/mka.v35.i1.p50-60.2011.

Full text

Abstract:

AbstrakMelaporkan kasus Limpoma pada Mata yang dirawat di RS. Dr. M. Djamil Padang.Studi retrospektif dari 17 rekam medik yang didiagnosa sebagai limfoma pada mata di Bagian Mata RSUP dr. M. Djamil antara 2003 – 2010.Terdapat 17 kasus limfoma pada mata di RSUP Dr. M. Djamil antara 2003 – 2010. Pasien laki-laki sebanyak 15 orang dan pasien perempuan 2 orang, dengan usia antara 4 bulan – 71 tahun. Keluhan utama paling sering (82,35%) adalah proptosis pada mata. Semua pasien diperiksa dengan CT scan dan pemeriksaan histopatologis. Tipe limfositik yang paling banyak ditemukan secara histopatologis (64,70%). Semua pasien dianjurkan untuk kemoterapi, tetapi hanya 10 pasien yang menjalani kemoterapi.Proptosis pada mata merupakan tanda yang paling sering dari limfoma maligna pada pasien yang berobat di RSUP Dr. M. Djamil. Tipe limfositik adalah tipe yang paling sering. Tidak semua pasien menjalani kemoterapi karena adanya masalah ekonomi.Kata kunci: Limfoma maligna, limfoma pada mata, proptosisAbstractReporting cases of hospitalized ocular lymphoma at Dr. M. Djamil Hospital from 2003 – 2010.Retrospective study of the medical records of 17 Ocular Lympomas diagnosed patients at the Ophthalmology Department of Dr. M. Djamil Hospital, between 2003 – 2010.There were 17 cases of Ocular Lymphoma at Dr. M. Djamil Hospital between 2003 – 2010. They are 15 male and 2 female patients, in range of age between 4 months to 71 years old. Most of them (82.35%) have chief complaint proptosed of the eye since months to years. All patients were examined using CT imaging and histopatologically. Lymphosityc type was the most type of hystopathological characterictic (64.70%) All patient were suggested to chemotherapy, but only 10 patients received chemotherapy.LAPORAN KASUS51Proptosed of the eye was the most commont sign of malignant lymphoma patient visited at Dr. M. Djamil Hospital. Lymphosityc type was the most common type. Not all patients could receive chemotherapy for they have economic problems.Key word : Malignant lymphoma,ocular lymphoma, proptosis

APA, Harvard, Vancouver, ISO, and other styles

18

Cannata-Ortiz, Jimena, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Maria José Requena, Concepción Alaez, Adrian Alegre, and Reyes Arranz. "The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs. LNH-pro-05 trial)." Blood 116, no. 21 (November 19, 2010): 2867. http://dx.doi.org/10.1182/blood.v116.21.2867.2867.

Full text

Abstract:

Abstract Abstract 2867 Introduction. Survival of Follicular Lymphoma patients has significantly increased with the introduction of immunomodulatory agents, such as Interferon (IFN) and Rituximab (R). Until 2002 our Follicular Lymphoma patients were included in a trial and received induction therapy with CVP + Interferon (LNH-pro, JCO 16; 1538–1546). Since 2006, Rituximab is being added to the same induction regimen (LNH-pro-05, EHA 09). Herein we communicate the comparative results between these two trials in Intermediate-High risk Follicular Lymphoma patients. Aim. To compare toxicity and efficacy in terms of complete remission (CR) and Progression Free Survival (PFS) between both trials in Intermediate-High risk Follicular Lymphoma patients. Methods. Patients in the LNH-pro trial (1990-2006) received CVP (CY 400mg/m2 p.o D1-5, VCR 1.4mg/m2 iv D1, PRD 100mg/m2 po D1-5) + IFN (3MU/m2 sc, 3 times/wk, for 12 wks). When it became available, G-CSF support was permited. In the LNH-pro-05 trial (2006-ongoing), Rituximab (R: 375mg/m2 iv D1) was added to the same induction regimen. All patients received 8 cycles as per protocol, with G-CSF support and Pn. jiroveci prophilaxis. In both studies, complete re-assessment was performed after cycle 4, at the end of induction therapy, every 4 months for the first 2 years and every 6 months thereafter. Results. We analysed data from 74 and 36 FL patients with FLIPI≥2, included in the LNH-pro and LNH-pro-05 trials, respectively. Patients' characteristics are shown in table 1. No significant differences were found between groups, except for a higher incidence of elevated B2-microglobulin in patients treated with CVP+IFN and higher Bulky disease (>7cm) among patients with R+CVP+IFN. Median number number of cycles were 6 and 8, respectively. Response: Seventy one patients (96%) in the LNH-pro Trial (CVP+IFN) were evaluable for response. Overall Response (OR) rate was 87%, with 68% Complete Remission (CR) and 19% Partial Remission (PR) (9% non-responders). In the LNH-pro-05 Trial (R+CVP+IFN), 36 patients (92%) and 33 patients (83%) were evaluable for response after 4th and 8th cycle. At cycle 4, all assesed patients achieved remission (15% PRs and 85% CR+uCR), while after the 8th cycle 100% of patients are in CR or uCR. Toxicity. Main hematologic grade 3–4 toxicity was neutropenia, 33% for CVP+IFN and 28% for R+CVP+IFN, with 12% and 6% of infections, respectively. Other non-hematologic toxicities were infrequent and mild (5% and 10% in each group). Eight percent of patients in the LNH-pro trial withdrew treatment due to toxicity. At the moment, none of the patients in the LNH-pro-05 trial have experienced an unacceptable toxicity. Survival . Median follow-up was 7.7 years for CVP+IFN and 2 years for R+CVP+IFN. A significant increase of PFS was seen among patients who received R (66% vs. 86%, at 3 years, P 0.05). There is also a trend to a longer overall survival in patients treated with R+CVP+IFN (P 0.07). Conclusion. The addition of Rituximab to CVP+IFN induction regimen in Intermediate-High risk Follicular Lympoma patients, significantly increases complete remission rates (88% to 100%) and progression free survival (86%, at 3 years), with a low toxicity profile. Disclosure: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

19

Arne, Kolstad, Anna Laurell, Mats Jerkeman, Kirsten Grønbæk, Erkki Elonen, Riikka Räty, Lone Bredo Pedersen, et al. "Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin." Blood 120, no. 21 (November 16, 2012): 747. http://dx.doi.org/10.1182/blood.v120.21.747.747.

Full text

Abstract:

Abstract Abstract 747 The outcome of mantle cell lympoma (MCL) has improved in recent years. The Nordic Lymphoma Group has since 1996 completed three consecutive phase II trials for front-line treatment of MCL patients < 66 years of age. The first trial (MCL1) showed that quality of response prior to transplant was the most important factor for outcome. Hence, in the second trial (MCL2) induction therapy was intensified by adding cycles of high-dose Ara-C and rituximab to the regimen. Despite significant improvement in overall and progression-free survival, patients who did not achieve CR pretransplant had a shorter time to progression. Therefore, the main objective of the MCL3 study was to improve the time to progression in patients who achieved only CRu or PR pretransplant by adding Zevalin to the high-dose regimen as a late intensification. Results of the – otherwise largely identical - MCL2 trial serve as the historic control. Methods: Newly diagnosed stage II-IV MCL patients < 66 years received induction immunochemotherapy with alternating cycles of R- (rituximab) maxi-CHOP and R-Ara-C to a total of 6 cycles. Evaluation of pretransplant response with CT scans and bone marrow was performed after 5 cycles. PET/CT pretransplant was recommended, but would not influence treatment. Responding patients by NCI criteria underwent in-vivo purged stem cell harvest after the 6th cycle (Ara-C + 2 doses of rituximab). Patients in CRu or PR received a standard dose Zevalin (0.4 mCi/kg) one week prior to high-dose therapy with BEAM or BEAC while CR patients received the high-dose chemotherapy without Zevalin. Follow-up included CT-scans, bone marrow and blood sampling for at least 5 years, including PCR for minimal residual disease or molecular relapse. Patients in solely molecular relapse received preemptive therapy with 4 weekly doses of rituximab, as in the MCL2 study. Results: 161 consecutive patients were included from 2005–2009, with characteristics similar to that of the MCL2 trial with a median age of 57 years (28–65), a male predominance and the majority in stage IV with bone marrow involvement. Only 12 out of 161 patients (7 %) did not receive a transplant, 6 due to stem cell harvest failure, 2 due to toxicity and 4 due to no response to induction treatment. Before transplant 50% were in CR, 17% in CRu, and 30% in PR. Only four out of 161 patients (2 %) did not respond to induction treatment. After a median follow-up of 3.2 years the projected 5-year overall and event free survival, and time to progression were 71, 55 and 65% respectively and the MCL2 and MCL3 curves were superimposable. Of the 69 candidates to Zevalin in CRu/PR according to protocol, 65 (94%) actually received this treatment. There was no significant difference in time to progression for patients in CRu and PR pretransplant between MCL2 and MCL3, indicating no effect of late intensification with Zevalin in MCL3 in this patient group. Interestingly, a positive pretransplant PET scan proved to be a strong negative predictor for outcome. Lack of benefit from addition of Zevalin to the high-dose regimen was shown for both PET-positive and PET-negative patients. In a multivariate analysis of the impact of clinical response, PET positivity and zevalin treatment, only PET positivity pretransplant had independent significance (p=0.0003 HR=3.412 (95% confidence limits 1.744 – 6.673). The treatment-related mortality was 3 %. Side-effects were similar to that previously reported for MCL2, and we did not find that Zevalin added any toxicity. Of the 3 patients who developed secondary MDS/AML posttransplant, two had received Zevalin and one had not. Conclusion: The MCL3 data confirm the good results and tolerability of the Nordic regimen. However, the late intensification with Zevalin, albeit non-toxic, did not prolong the time to progression for patients in only CRu or PR pretransplant. A positive PET prior to transplant was shown to be a strong negative predictor for outcome. The concept of late intensification may be too late in poor responders. In consequence, up-front intensification with increasing use of high-dose AraC for MIPI high-risk patients is used in the subsequent, now ongoing Nordic-British MCL5 study. Disclosures: Arne: Bayer Schering Pharma: Research Funding. Geisler:Roche, Schering: Consultancy, Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Lympohma'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles